A high drug failure rate is more than just a pattern recognition problem. Here's how we can address some of the root causes.

Middle molecules with a molecular weight of more than 1,000 are difficult to synthesize due to multiple steps and time-consuming nature, demanding the development of a new approach that can overcome ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

New drugs are typically approved based on highly ... Such behaviour breeds inefficiency, mistrust, and uncertainty within the drug development process, increasing costs. Fortunately, blockchain ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.

A report in the journal Science from researchers in the UW–Madison Department of Chemistry represents a significant advance in making the types of molecules needed in drug development.

Nature Medicine has been chronicling advances in medical technology and health care. To mark the journal’s 30th anniversary, each month ...

Traditionally, drug development has been a lengthy, costly, and uncertain process. However ... and quicker access to new medicines for patients. This convergence of AI and biotechnology, referred ...

LinkedIn founder and venture capitalist Reid Hoffman has just launched drug discovery startup Manas AI, alongside Dr.